Registration and Continental Breakfast—Exhibits Open

7:30 a.m.

Welcome and Opening Remarks—Overview and History of Stem Cell Transplantation at Emory, Edmund K. Waller, MD, PhD, Emory University School of Medicine, and OptumHealth Education

8:00 a.m.

Advances and the Role of Transplant and Clinical Trials in Myeloma Therapy, Sagar Lonial, MD

Objectives:

1. Compare the difference between two- and three-drug inductions for multiple myeloma (MM).
2. Discuss the impact of genetics on treatment outcomes.
3. Realize the timing and role of autologous transplant for MM.

8:45 a.m.

Optimizing the Conditioning Regimen and Stem Cell Collection for Patients Undergoing Autologous Stem Cell Transplantation, Jonathan Kaufman, MD

Objectives:

1. Review standard collection procedures for autologous transplant.
2. Describe specific procedures that result in safe, efficient and high quality collections.
3. Examine standard conditioning regimens for the most common indications for stem cell transplant (myeloma, lymphoma, Hodgkin disease, germ cell tumors).
4. Discuss investigational approaches for conditioning regimens whose goal is to improve efficacy and safety.

9:30 a.m.

Break—Exhibits Open

10:00 a.m.

The Role of Stem Cell Transplantation in Hodgkin’s and Non-Hodgkin’s Lymphoma in the Era of Targeted Therapies, Jonathon Cohen, MD

Objectives:

1. Discuss the role of autologous and allogeneic stem cell transplant in Hodgkin’s and non-Hodgkin’s lymphoma.
2. Describe the new non-transplant-related targeted agents in non-Hodgkin’s lymphoma and their impact on timing of transplant.
3. Review ways to evaluate patients with newly diagnosed and relapsed lymphoma.

10:45 a.m.

Allogeneic Transplant for Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) in the Modern Era, Jean Khoury, MD

Objectives:

1. Review outcomes for the treatment of Chronic CML and ALL.
2. Discuss the outcomes of allogeneic transplantation in CML and ALL.
3. State the indications for allogeneic transplantation for ALL in first remission (CR1 and second remission (CR2).

11:30 a.m.

Lunch (provided)—Exhibits Open

12:45 p.m.

Preventing Graft-Versus-Host Disease (GVHD) in Allogeneic Stem Cell Transplant: What is the Optimal Transplant Regimen? Zaid Al-Kadhimi, MD

Objectives:

1. Define GVHD and its impact on transplant outcomes.
2. Discuss donor-, recipient- and transplant-related factors associated with higher risk for GVHD.
3. Analyze current and new methods for GVHD prevention.

1:30 p.m.

How Psychosocial Issues Impact Transplant, Alice Mullins, LCSW

Objectives:

1. Discuss psychosocial issues in bone marrow transplant (BMT).
2. Identify resources and strategies to assist patients through transplant.
3. List limitations in the research of psychosocial variables and survival after BMT.
4. Discuss a patient’s experience with BMT.

Multiple Myeloma–A Patients Experience Through Transplantation, Danielle Spann

Objectives:

1. Describe each step of the transplant process from a patients perspective.
2. Identify questions to ask during the transplant evaluation.
3. List helpful resources for patients with multiple myeloma undergoing stem cell transplantation.

2:30 p.m.

Break—Exhibits Open

2:45 p.m.

The Road Less Traveled: Stem Cell Transplants for Aplastic Anemia and Germ Cell Cancer, Edmund K. Waller, MD, PhD

Objectives:

1. Describe the pathogenesis and initial management of aplastic anemia.
2. State the role of allogeneic transplantation in the management of aplastic anemia.
3. Review the role of high-dose chemotherapy and autologous stem cell support in the management of relapsed/refractory germ cell cancer.

3:30 p.m.

When to Offer Allogeneic Transplants for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) and How Much Conditioning Is Needed? Amelia Langston, MD

Objectives:

1. State current prognostic scoring systems for AML and MDS and their relevance regarding indications for transplantation.
2. Discuss the expected outcomes of transplantation, depending on disease and disease status at the time of transplant.
3. Review the spectrum of conditioning regimens for transplantation and the patient and disease considerations that figure into the final treatment plan.

4:15 p.m.

Stem Cell Transplant—Question and Answer Panel, Amy Langston, MD;  Edmund K. Waller, MD, PhD; and Sagar Lonial, MD

4:45–6:15 p.m.

Get Acquainted Reception
Please join us for complimentary drinks and hors d’oeuvres. This unique evening will provide attendees the opportunity to get further acquainted with staff members from the Emory Transplant Center and Winship Cancer Institute.

7:00 a.m.

Registration and Continental Breakfast—Exhibits Open

7:30 a.m.

Welcome and Opening Remarks—Overview of Emory Transplant Center, Thomas Pearson, MD, PhD

7:45–9:00 a.m.

UPDATES IN IMMUNOSUPPRESSION

The Creation of a New Immunosuppressant Paradigm—Belatacept from Mouse through BENEFIT, Christian Larsen, MD, PhD

Objectives:

1. Explain the discovery, translation, and regulatory steps necessary for the development and FDA approval of the costimulation blocker Belatacept for use in renal transplantation.
2. State the mechanism of action of the costimulation blocker Belatacept in transplantation.
3. Recognize the benefits of using costimulation blockade vs. calcineurin inhibitors in renal transplantation.

The Emory Belatacept Experience—Tracking Outcomes to Improve Quality, Stephen Pastan, MD

Objectives:

1. Review the development of the Emory protocol for use of Belatacept as a first-line immunosuppressive agent.
2. Identify common adverse events that occur in kidney transplant patients in the first posttransplant year.
3. Analyze the use of real-time clinical outcome data to continuously improve the immunosuppressive protocol through a multidisciplinary quality-improvement process.

Scientific Discovery in Transplantation Research—Next Generation Immunosuppression, Mandy Ford, PhD

Objectives:

1. Explain the immunological processes that are likely to result in “breakthrough” rejection under current immunosuppressive regimens.
2. Review novel strategies to inhibit donor-reactive immune responses in transplantation.
3. Describe how the immunological “signature” of a given transplant recipient may predict how well they respond to immunosuppression

Updates in Immunosuppression—Questions and Answers

9:00 a.m.

Break—Exhibits Open

9:30 a.m.

Transplanting Sensitized Patients: Paired Donor Exchange, Kenneth Newell, MD, PhD

Objectives:

1. State the potential advantages of participating in a paired donor exchange program.
2. Identify factors that limit the broader application of paired donor exchange programs.
3. Appreciate the current status of paired donor exchange programs within the United States.

10:15 a.m.

Identifying and Eliminating Racial Disparity in Access to Transplant: Focus on the Southeast, Rachel Patzer, PhD

Objectives:

1. Illustrate access to kidney transplantation across geographic regions.
2. Explain variability in dialysis-facility-level access to kidney transplantation.
3. Provide examples of solutions for reducing barriers in access to early steps of the kidney transplant process.

11:00–11:45 a.m.

GROWING AND IMPROVING OUTCOMES FOR TRANSPLANT—PART 1

Liver Transplantation—Growing and Improving Outcomes, Stuart Knechtle, MD

Objectives:

1. Explain how a quality-improvement program can be implemented in a transplant program.
2. Discuss how process improvement occurs within a liver transplant program.
3. Describe how program growth develops from planning efforts.

Expanding the Donor Pool—Use of Expanded Criteria (ECD) and High-Risk Liver Donors, B. Daniel Campos, MD

Objectives:

1. State the reasoning behind the use of ECD and high-risk liver donors.
2. Define ECD and high-risk liver donors and list the recipient selection for each.
3. Identify perioperative considerations when transplanting an ECD or high-risk liver.
4. State the outcomes of liver transplants derived from ECD and high-risk donors.

11:45 a.m.–1:00 p.m.

Lunch (provided)—Exhibits Open

1:00–1:45 p.m.

GROWING AND IMPROVING OUTCOMES FOR TRANSPLANT—PART 2

Transplantation for Liver Cancer, a Multidisciplinary Approach—Past, Present and Future, Andrew Adams, MD, PhD

Objectives:

1. Define the role for liver transplant for patients with hepatocellular carcinoma.
2. Discuss the use of liver transplant in the treatment of hilar cholangiocarcinoma.

Expanding the Liver and Lung Donor Pool, Organ Perfusion, Joseph Magliocca, MD, and David Neujahr, MD

Objectives:

1. Review the current criteria for acceptable lung donors in the United States.
2. Recognize that donor availability limits the potential benefit of lung transplantation for patients with end-stage lung disease.
3. Explain the potential role for ex-vivo lung perfusion in improving donor lungs that do not meet the prior standards for donation.

Growing and Improving Outcomes for Transplant—Questions and Answers

1:45 p.m.

Bridging Liver Failure to Liver Transplant—Molecular Adsorbents Recirculating System (MARS) / Extracorporeal Liver Assist Device (ELAD), Ram Subramanian, MD

Objectives:

1. State the rationale for the need for extracorporeal liver support.
2. Explain the classifications of liver failure.
3. Review current modalities of extracorporeal liver support.
4. Propose future applications of liver support.

2:30 p.m.

Break—Exhibits Open

2:45 p.m.

The Obesity Epidemic and Nonalcoholic Steatohepatitis (NASH)—When to Refer and How to Manage, John Paul Norvell, MD

Objectives:

1. Define the epidemic of metabolic syndrome and NASH in the United States.
2. Explain the current management of patients with NASH cirrhosis and the appropriate role of referral and selection for liver transplantation.

3:30 p.m.

Hepatitis C—Past Present and Future, Ryan Ford, MD

Objectives:

1. Discuss the epidemiology and current status of patients with chronic hepatitis C in the United States.
2. Review the consequences of untreated hepatitis C in the United States.
3. Identify new medical therapies that may offer a cure for this virus, and compare these regimens to those previously used.

4:15–5:00 p.m.

Liver Transplantation in Special Populations, James Spivey, MD

Objectives:

1. Explain what comprises “difficult” candidates for transplantation.
2. State the specific challenges associated with pre- and postoperative care of difficult populations.
3. Recognize areas wherein improvement might be made in providing opportunity for special populations.